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Purpose: Although elevated blood pressure (BP) predicts future cardiovascular events, 
recommended BP targets often is not reached in the general community. In a clinical real-life 
setting we evaluated BP impact and tolerability of the angiotensin-II receptor blocker telmisartan 
in patients with essential hypertension.
Patients and methods: Patients in this observational study not at target BP started or 
switched to telmisartan monotherapy (40 or 80 mg) or a fixed-dose combination of telmisartan   
and hydrochlorothiazide (HCT) 80 mg/12.5 mg. Office and 24-hour ambulatory BP (AMBP) 
were measured before and after 8 weeks of treatment and physicians reported perceived drug 
efficacy and tolerability as “Very good”, “Good”, “Moderate” or “Bad”.
Results: 100 patients (34% female, 60 years, BMI 29.4 kg/m2, mean office BP 159/92 mmHg) 
of whom 38% were treatment naïve and 30%, 17%, 9% and 6% respectively were on 1, 2, 3 or 
4 BP-lowering drugs, completed 8 weeks of treatment. The proportion of patients with office 
BP  140/90 mmHg increased from 3% to 54% for systolic (P  0.001), 38% to 75% for 
diastolic (P  0.001), and 2% to 45% for systolic and diastolic BP (P  0.001). A significant 
effect on BP levels was seen in patients being either treatment naïve or on 1 to 3 BP-lowering 
drugs at study entry, whereas no BP improvement occurred in those who switched from 4 drugs. 
Overall, mean 24-hour AMBP was reduced from 141/85 to 131/79 mmHg (P  0.001). Drug 
efficacy and tolerability were perceived as “Very good” or “Good” by 44%/34% and 66%/27%, 
respectively. No drug discontinuations or serious adverse events were observed.
Conclusions: In this observational study, telmisartan 40 to 80 mg, or the fixed-dose combination 
telmisartan 80 mg/HCT 12.5 mg, significantly increased the number of patients reaching target 
BP  140/90 mmHg if treatment naïve or previously receiving 1 to 3 BP-lowering drugs. The 
BP reduction achieved was sustained for 24-hour and treatment tolerability was high.
Keywords: telmisartan, tolerability, efficacy, 24-hour ambulatory blood pressure, observational 
study
Background
Elevated blood pressure (BP) increases the risk for cardiovascular (CV) morbidity 
and mortality1–4 in a curvilinear relation, starting at 115/75 mmHg, irrespective of 
age and gender. The BP-related CV risk is accentuated in the presence of other CV 
risk factors or co-morbidities such as diabetes mellitus, obesity, metabolic syndrome 
and dyslipidemia.5
This is of concern as the prevalence of hypertension is high, eg, 28.4% in a survey 
among US residents from 2000,6 and on the rise; a significant 10% increase was seen 
in the National Health and Nutrition Examination Surveys (NHANES) between 1988 
and 2004.7 The cause for this development is multifactorial, eg, increasing prevalence Vascular Health and Risk Management 2010:6 32
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of diabetes and obesity and increased life expectancy, which 
all are factors associated with increased cumulative lifetime 
risk for hypertension.5
Pharmacological BP-lowering contributes to CV disease 
prevention. Hence, several institutional bodies have issued 
BP treatment guidelines (eg, the Joint National Commit-
tee on Prevention, Detection, Evaluation, and Treatment 
of High Blood Pressure [JNC-VII]),8 the American Heart 
Association9 and the European Societies of Hypertension 
and Cardiology.10 Most of these agree on a treatment goal 
of 140/90 mmHg in uncomplicated essential hypertension. 
However, despite such guidelines and the prevailing high 
number of anti-hypertensive agents,11 BP treatment goals 
are often not reached in hypertensive patients. It is believed 
that only approximately 25% to 40% of the treated subjects 
in the community are at target BP levels,12,13 which is in 
line with the NHANES examination 1999–2000 where 
only 31.0% of hypertensive patients were controlled to a 
BP of  140/90 mmHg.5 The cause for this may be both 
patient and physician related; eg, side effects or low efficacy of 
BP drugs, physicians resistance to supplement or dose escalate 
initiated treatment (as often 2 BP drugs are needed) and a 
low public awareness of CV benefits of BP control.3,14
In the present study, in a “real-world” setting of hyperten-
sive patients in primary care not at target BP levels we wanted 
to evaluate BP responses (office- and 24-hour ambulatory-BP 
(AMBP) profiles), occurrence of side effects, and physician-
perceived drug efficacy and tolerability of  the oral angiotensin II 
receptor blocker, telmisartan (Micardis®; Boehringer Ingel-
heim Pharma, Germany). Telmisartan reduces BP by block-
ing vasoconstriction, sodium retention, and aldosterone and 
vasopressin production caused by angiotensin II.15
Methods
This was a prospective, nonrandomized, multicenter obser-
vational study (The Telmimore study [A clinical survey of 
the antihypertensive effects of telmisartan in patients with 
mild-to-moderate hypertension]) of patients recruited by 
25 general practitioners (GPs) in the middle, western and 
south-eastern regions of Norway serving approximately 
20000 to 25000 subjects. Patients with essential hyperten-
sion not at target BP, who were prescribed telmisartan by the 
physician on clinical indication, were eligible for inclusion. 
Informed written consent was obtained from all participants. 
The study was performed in accordance with the Helsinki 
Declaration and approved by the Regional Ethical Committee.
Patients were enrolled between June 2006 and June 2007, 
and remained under the care of the GPs for the duration of 
the study that was 8 weeks. At enrolment, a general clinical 
examination was performed and weight, height, data concern-
ing past medical history (including coronary heart disease, 
diabetes mellitus, hypercholesterolemia, atrial fibrillation, 
chronic obstructive pulmonary disease, and cerebrovascular 
disease), and current medication were recorded in a case report 
form (CRF). Office BP was measured on the non-dominant 
arm with a random zero mercury sphygmomanometer using 
appropriate cuff size in sitting position after 5 minutes of 
rest. A mean of two measurements was recorded. 24-hour 
AMBP measurements were performed, utilizing an oscillo-
metric equipment, on the nondominant arm using appropriate 
cuff size (Welch Allyn AMBP 6100, Skaneateles Falls, NY, 
USA), starting between 10:00 am and 12:00 am. Reading 
intervals were 15 minutes from 07:00 am to 11:00 pm and 
30 minutes from 11:00 pm to 07:00 am. 24-hour AMBP 
means were computed with weights according to the time 
interval between successive readings. Recordings with more 
than 80% of valid measurements and which had at least one 
reading per time-period during night-time and early morning 
hours were considered valid.16
At study entry, patients not at target BP either started 
(if treatment naïve), or were switched to (if already 
on BP-lowering drugs) treatment with telmisartan 40 mg, 
80 mg, or a fixed-dose combination of telmisartan 80 mg/
hydrochlorothiazide (HCT) 12.5 mg. The BP effect was 
evaluated after 8 weeks. At this final visit the same data as 
on study entry were recorded together with a questionnaire 
for the GPs to be filled in concerning perceived drug efficacy 
and tolerability. Answer options on the questionnaire were 
divided in “Very good”, “Good”, “Moderate”, “Bad” or “Not 
determined”. Possible adverse events during the study were 
detailed in the CRF.
Data analysis was performed using SPSS statistical 
software version 16.0 for Windows (SPSS Inc. Chicago, 
USA). Data on continuous variables are presented as mean 
and standard deviation unless otherwise stated. Analysis of 
continuous variables was performed by paired t-test or a 
bivariate correlation where appropriate. Categorical variables 
are presented as counts or proportions (%) and by statisti-
cal comparisons of these parameters the chi-square test or 
Fisher’s exact test were utilized. Sample size was determined 
based on estimated improvements in proportion of subjects 
at treatment goal from 30% to 45%. The null hypothesis was 
based on no difference in this proportion. A total number 
of 86 participants needed was estimated from a statistical 
power of 90% and an alpha error level of 5%. A two-sided 
P-value of  0.05 was regarded as statistically significant.Vascular Health and Risk Management 2010:6 33
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Results
A total of 103 Caucasian patients was enrolled in the 
study. Three patients were lost to 8 weeks follow-up, 
thus 100 patients were eligible for statistical analyses. Of 
these, 38 patients (38%) were treatment naïve. Baseline 
characteristics of the study cohort are given in Table 1. 
The BP was high (mean systolic BP 159 ± 13 and mean 
diastolic BP 92 ± 10 mmHg) irrespective of medical treat-
ment. Mean BMI was high, adjunctive treatment with statins 
was relatively low despite substantial co-morbidity, and few 
patients were on treatment with betablockers. Telmisartan 
monotherapy 40 to 80 mg (mean dosage 52 mg) was given 
to 49 patients (49%) and the fixed-dose telmisartan 80 mg/ 
HCT 12.5 mg to 51 patients (51%).
Effects on office BP
Telmisartan treatment for 8 weeks was associated with a 
statistically significant reduction in systolic and diastolic 
BP, both in treatment naïve patients (BP difference 
–24/–14 mmHg, P  0.001 for both) and in patients on 
1, 2, or 3 BP-lowering drugs at study entry (BP difference 
–7/–9 mmHg, [P  0.001 for both], –26/–7 mmHg 
[P  0.001 for both], and –10/–4 mmHg [P  0.01 for 
systolic BP only] respectively) (Table 2).
The BP reduction (both systolic and diastolic) for the 
whole cohort tended to be more pronounced in patients given 
the fixed-dose telmisartan 80 mg/ HCT 12.5 mg than in those 
receiving telmisartan monotherapy if previously treated with 
BP-lowering drugs (Table 3). No statistically significant dif-
ference in BP was seen in the six patients switching from a 
previous combination therapy of 4 BP-lowering drugs to a 
telmisartan based regimen (Table 3).
The  proportion  of  patients  at  target  BP  levels 
of  140/90 mmHg increased from 2% at study entry to 
45% after 8 weeks of telmisartan treatment, and did not 
differ between the three telmisartan regimens (40 mg: 46%, 
Table 1 Baseline data for 100 hypertensive patients completing 8 weeks of treatment with telmisartan with or without HcT
Total cohort Treatment-naïve 1 BP drug 2 BP drugs 3 BP drugs 4 BP drugs
n 100 38 30 17 9 6
Age (years) 60 ± 13 54 ± 12 63 ± 14 64 ± 12 65 ± 9 62 ± 6
gender (female/male) 34/66 16/32 12/18 5/12 1/8 0/6
BMi (kg/m2) 29.4 ± 4.7 30.4 ± 5.7 28.4 ± 3.9 28.0 ± 4.5 29.8 ± 2.7 30.7 ± 4.2
Duration of hypertension
1 year 39 (39%) 29 (76%) 10 (33%) 0 (0%) 0 (0%) 0 (0%)
1–5 years 24 (24%) 6 (16%) 12 (40%) 5 (29%) 0 (0%) 1 (17%)
5 years 37 (37%) 3 (8%) 8 (27%) 12 (71%) 9 (100%) 5 (83%)
Concomitant disease
coronary heart disease 11 (11%) 0 (0%) 2 (7%) 3 (18%) 4 (44%) 2 (33%)
cerebrovascular disease 5 (5%) 1 (4%) 3 (10%) 1 (6%) 0 (0%) 0 (0%)
Atrial fibrillation 5 (5%) 0 (0%) 2 (7%) 2 (12%) 0 (0%) 1 (17%)
Diabetes mellitus 10 (10%) 6 (16%) 2 (7%) 0 (0%) 0 (0%) 2 (33%)
cOPD 6 (6%) 3 (8%) 3 (10%) 0 (0%) 0 (0%) 0 (0%)
Dyslipidemiaa 26 (26%) 5 (13%) 6 (20%) 4 (24%) 7 (78%) 4 (67%)
Previous treatment and BP related parameters
Beta-blockers 15 (15%) 0 (0%) 2 6 (35%) 3 (33%) 4 (67%)
Diuretics 32 (32%) 0 (0%) 13 7 (41%) 8 (89%) 4 (67%)
ARB 29 (29%) 0 (0%) 9 8 (48%) 7 (78%) 5 (83%)
Ace inhibitor 8 (8%) 0 (0%) 2 4 (24%) 2 (22%) 0 (0%)
ccB 18 (18%) 0 (0%) 3 4 (24%) 6 (67%) 5 (83%)
Other 13 (13%) 0 (0%) 1 5 (29%) 1 (11%) 6 (100%)
sys BP (mmHg) 159 ± 13 160 ± 12 155 ± 13 163 ± 11 156 ± 11 162 ± 19
Dia BP (mmHg) 92 ± 10 97 ± 9 91 ± 9 86 ± 9 88 ± 11 90 ± 6
HR (bpm) 74 ± 10 76 ± 10 71 ± 12 70 ± 8 77 ± 9 79 ± 7
aOn statin therapy.
Notes: Data are given as mean ± SD (continuous variables) and as counts (n) or % (categorical variables).
Abbreviations: HcT, hydrochlorothiazide; BP, blood pressure; BMi, body mass index; cOPD, chronic obstructive pulmonary disease;   ARB, angiotensin ii receptor 
blocker;   Ace, angiotensin converting enzyme; ccB, calcium channel blocker; sys, systolic; dia, diastolic; HR, heart rate; bpm, beats per minute.Vascular Health and Risk Management 2010:6 34
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80 mg: 43%, 80 mg/HCT 12.5 mg: 43%) (Table 4). The 
corresponding increase in the proportion reaching systolic 
BP target only was 3% to 54%, and diastolic BP target only 
38% to 75% (P  0.001 for all comparisons) (Table 4).
Effects on 24-hour AMBP
In total, 75 patients (75%) agreed to have 24-hour AMBP 
measurements performed. The baseline characteristics of 
these did not differ significantly from those of the total 
cohort. Data were lacking for 5 patients at baseline and for 
1 patient at follow-up. Thus, 24-hour AMBP recordings 
were available for statistical analyses in 69 patients.
Telmisartan treatment for 8 weeks was associated with a 
statistically significant reduction in mean 24-hour AMBP in 
the whole study cohort (mean systolic/diastolic BP baseline: 
141/85 mmHg; at 8 weeks: 131/79 mmHg, P  0.001 for 
both, Figure 1a). Furthermore, in treatment naïve patients 
(Figure 1b), as well as in those on 2 BP-lowering drugs at 
study entry (Figure 1d), a significant reduction for both 
24-hour mean systolic and diastolic BP was observed, 
whereas in patients switching from 1 study drug to telmis-
artan a significant reduction was seen only for the mean 
24-hour diastolic BP (Figure 1c), with a trend for systolic 
BP reduction (P = 0.085). There was a positive correlation 
between 8-week changes in systolic office and mean 24-hour 
AMBP (r = 0.54, P  0.001, n = 69). No impact was seen on 
mean 24-hour heart rate (baseline 73.6 ± 12.2 vs 74.1 ± 12.1 
at 8 weeks).
Tolerability and safety
Telmisartan was classified as being efficacious and well 
tolerated by most GPs (“Very good”: 44% and 66%, and 
Table 2 Impact on office BP 8 weeks after initiating or switching to telmisartan with or without HCT (any regimen) according to 
baseline number of BP-lowering drugs
Total cohort Treatment-naïve 1 BP drug 2 BP drugs 3 BP drugs 4 BP drugs
n 100 38 30 17 9 6
Baseline sys BP (mmHg) 159 ± 13 161 ± 13 155 ± 13 163 ± 11 156 ± 11 162 ± 19
study end sys BP (mmHg) 139 ± 14 137 ± 15 138 ± 14 137 ± 11 146 ± 13 153 ± 11
∆ sys BP (mmHg) −20 ± 16*** −24 ± 18*** −17 ± 16*** −26 ± 13*** −10 ± 9** −9 ± 12
Baseline dia BP (mmHg) 92 ± 10 97 ± 9 91 ± 9 86 ± 9 88 ± 11 90 ± 6
study end dia BP (mmHg) 82 ± 9 83 ± 9 81 ± 7 79 ± 7 77 ± 9 91 ± 11
∆ dia BP (mmHg) −10 ± 10*** −14 ± 10*** −9 ± 10*** −7 ± 7*** −4 ± 7 2 ± 4
Baseline HR (bpm) 74 ± 10 76 ± 10 71 ± 12 70 ± 8 77 ± 9 79 ± 7
study end HR (bpm) 70 ± 12 71 ± 9 69 ± 11 70 ± 8 79 ± 10 63 ± 28
∆ HR (bpm) −3 ± 12** −5 ± 11** −2 ± 14 0 ± 10 2 ± 8 −16 ± 33
Notes: Data are given as mean ± sD.
*P  0.05, **P  0.01, ***P  0.001.
Abbreviations: HcT, hydrochlorothiazide; sys, systolic; BP, blood pressure; dia, diastolic; ∆, delta (ie, BP change from baseline to study end); HR, heart rate; bpm, beats per 
minute.
Table 3 Effect of telmisartan therapy on office BP at 8 weeks according to baseline number of BP-lowering drugs
Telmisartan 40 mg Telmisartan 80 mg Telmisartan 80 mg/HCT 12.5 mg
n ∆ sys BP 
(mmHg)
∆ dia BP 
(mmHg)
n ∆ sys BP 
(mmHg)
∆ dia BP 
(mmHg)
n ∆ sys BP 
(mmHg)
∆ dia BP 
(mmHg)
Total cohort 28 −18 ± 17*** −9 ± 11*** 21 −18 ± 20*** −10 ± 11*** 51 −22 ± 14*** −9 ± 10***
Treatment-naïve 19 −18 ± 18*** −11 ± 10*** 6 −28 ± 24* −19 ± 15* 13 −30 ± 12*** −15 ± 8***
1 BP drug 5 −14 ± 16 −5 ± 10 10 −9 ± 13 −7 ± 7* 15 −23 ± 15*** −13 ± 11***
2 BP drugs 3 −30 ± 9* −10 ± 13 4 −29 ± 23 −8 ± 6 10 −23 ± 10*** −7 ± 5**
3 BP drugs 1 −2 6 1 −10 1 7 −12 ± 10* −6 ± 6*
4 BP drugs 0 n/A n/A 0 n/A n/A 6 −9 ± 12 2 ± 9
Notes: Data are given as mean ± sD and as counts (n).
*P  0.05, **P  0.01, ***P  0.001.
Abbreviations: HcT, hydrochlorothiazide; ∆, delta; sys, systolic; dia, diastolic; BP, blood pressure; n/A, not applicable.Vascular Health and Risk Management 2010:6 35
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“Good”: 34% and 27%, respectively) (Table 5). Serious 
adverse events did not occur and no patients discontinued 
the treatment. Adverse events occurred in 9 cases: bronchitis, 
enteritis, arthralgia, rhinitis, mouth dryness, hypotension, leth-
argy, pollakissuria, and tiredness, of which the latter 5 were 
assumed by the GPs as potentially being drug related.
Discussion
Starting telmisartan (either monotherapy in a dosage of 40 to 
80 mg, or a fixed-dose of telmisartan 80 mg/HCT 12.5 mg) 
did significantly improve BP in patients both previously 
treatment naïve and in those on treatment with 1, 2 or 3 BP-
lowering drugs. This indicates that telmisartan, with or without 
HCT, has a potent BP-lowering effect that can be useful in a 
substantial number of patients with arterial hypertension.
The treatment response in the current study is concor-
dant with results from other series exploring the effect of 
telmisartan in a community setting.17,18 This applies also to 
the high tolerability and low incidence of side effects seen 
in our study. The observed inverse relation between treat-
ment effect and number of previous BP drugs used is not 
surprising, as many patients with BP polypharmacy in fact 
do have a refractory hypertension which also could apply 
to telmisartan.
As anticipated, the proportion of patients treated to target 
at study entry was low (2%), however a substantial number 
had had their disease for many years (37% 5 years, 24% 
1 to 5 years) and 62% were receiving 1 to 4 BP-lowering 
drugs. Although the observed treatment effects of switch-
ing to telmisartan, with or without HCT, for those already 
on 1 to 3 BP-lowering drugs in most cases were reassuring, 
a substantial number of patients (55%) still was not at target 
after 8 weeks. Generic limitations of observational studies 
such as a relatively short treatment period and lack of a pre-
defined treatment algorithm including provision of guidelines 
for dose escalation may have contributed to this. However, 
clinical experience indicates that target values for BP may 
be difficult to reach for a substantial number of patients also 
in the “real world”.12,13
24-hour AMBP measurements as a means for more opti-
mal BP control are probably underused in clinical practice. 
In the current study we found it feasible to apply this method 
in a GP setting, and other trials have shown an educational 
value of this procedure even for the patient.19 Furthermore, 
24-hour AMBP, and especially 24-hour systolic BP, has been 
shown to have prognostic information above and beyond 
that of office BP.20 Thus, a more liberal use of this method 
in primary care should be advocated.21
The observed underuse of statins is in accordance with 
several surveys indicating that in the general community 
probably as much as 75% of patients are not treated accord-
ing to clinical guidelines.12
Limitations of the study, apart for generic limitations with 
any observational study, include the question whether the 
cohort is representative of the general hypertensive population. 
The baseline characteristics including co-morbidity indicate 
that this is true. Another limitation is that we can not rule out 
whether similar results could have been obtained by conducting 
this study with another design or by dose escalating the cur-
rent used drugs or by add-on of other drugs, since we have no 
Table 4 Percentages of patients within target office BP (140/90 mmHg) at baseline and study end (after 8 weeks of telmisartan with 
or without HcT) according to BP therapy at study entry
Total cohort Treatment naïve 1 BP drug 2 BP drugs 3 BP drugs 4 BP drugs
n 100 38 30 17 9 6
Baseline sys 
BP  140 mmHg
3% 0% 7% 0% 0% 17%
8 weeks sys 
BP  140 mmHg
54%*** 61%*** 57%*** 59%** 33%§ 0%
Baseline dia 
BP  90 mmHg
38% 18% 40% 65% 56% 50%
8 weeks dia 
BP  90 mmHg
75%*** 76%*** 80%** 88% 67% 33%
Baseline sys/dia 
BP  140/90 mmHg
2% 0% 3% 0% 0% 17%
8 weeks sys/dia 
BP  140/90 mmHg
45%*** 50%*** 47%** 53%*** 33%§ 0%
**P  0.01, ***P  0.001; §P = 0.059.
Abbreviations: BP, blood pressure; HcT, hydrochlorothiazide.Vascular Health and Risk Management 2010:6 36
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control group; we also did not assess treatment response based 
on what type of BP-lowering drug(s) were used (eg, calcium 
channel blockers, angiotensin receptor blockers, angiotensin 
conververting enzyme inhibtors) prior to the switch. Other 
limiting factors include the relatively small sample size, 
although this was fairly large for a 24-hour AMBP study. 
Further, an aspect that could limit the treatment response is 
that among included subjects, some were already at or near 
BP treatment targets at study entry. On the other hand, this 
“underevaluation” probably are balanced with the phenom-
enona of the open nature of the study, which was unavoidable, 
that could potentially lead to an impact on patients’ motivation 
to “do well” (the Hawthorne effect), thereby overestimating 
the treatment effect.
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Figure 1 24-hour ambulatory BP incl. mean ± sD at baseline and study end in A) total cohort (n = 69); and according to number of BP-lowering drugs at baseline: B) none 
(n = 31), C) 1 (n = 17), D) 2 (n = 9) and E) 3 or 4 (n = 12) drugs.
Notes: — Baseline hourly sys BP, … 8-weeks hourly sys BP,  --- Baseline hourly dia BP, -..- 8-weeks hourly dia BP, • Baseline 24-hour sys BP,  8-weeks 24-hour sys BP,   Baseline 
24-hour dia BP,  8-weeks 24-hour dia BP, *P  0.05, ***P  0.001, §P = 0.085.
Abbreviations: sys, systolic; BP, blood pressure; dia, diastolic.Vascular Health and Risk Management 2010:6 37
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In conclusion, in this observational study, 8 weeks 
treatment with telmisartan 40 to 80 mg or the fixed-dose com-
bination telmisartan 80 mg/HCT 12.5 mg significantly reduced 
BP in patients with hypertension being either treatment   
naïve or switching from 1 to 3 other BP-lowering drugs. The 
proportion of patients reaching target BP  140/90 mmHg 
was also significantly increased with telmisartan, with or 
without HCT, therapy. BP-lowering effects were sustained for 
24 hours and treatment tolerability was high.
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